# A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

> **NCT06024876** · EARLY_PHASE1 · COMPLETED · sponsor: **CorrectSequence Therapeutics Co., Ltd** · enrollment: 5 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **BIOLOGICAL:** CS-101

## Key facts

- **NCT ID:** NCT06024876
- **Lead sponsor:** CorrectSequence Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-26
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024876, "A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06024876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*